April 22, 2021
Business News

Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update


ALAMEDA, Calif.–()–Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2020 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

“I’m very proud of the Exelixis team’s execution in the fourth quarter and full year 2020 as we advanced all components of our business to enable top-line revenue growth in 2021 and beyond,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “Following the strong commercial performance of cabozantinib in the fourth quarter of 2020, Exelixis maintained momentum into 2021 with the FDA approval and…



Click here to view the original article.

Related Posts

You might also like ...

Omega Announces Quarterly Dividend and Schedules First Quarter Earnings Release Date and Conference Call
CRN Announces Launch of WellComms Conference for Marketing and Communications Professionals in Wellness Industries
Plaintiffs’ Counsel and Kaiser Permanente Announce $11.5 Million Equal Pay & Promotion Race Discrimination Class Action Settlement: The Settlement Provides Money Benefits and New Workplace Programs for African American Employees